Complete 1p/19q co-deletion, MGMT promoter methylation and IDH1 mutation which are associated with favorable outcomes in gliomas were more obvious in the low-risk group as risk scores increased (all p < 0.001, Spearman correlation, Fig. 4A, B). This evidence concerns the gene MGMT and central nervous system cancer.